CN1730023A - 一种抗肝炎病毒的中药制剂及其制备方法 - Google Patents
一种抗肝炎病毒的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN1730023A CN1730023A CN 200510090722 CN200510090722A CN1730023A CN 1730023 A CN1730023 A CN 1730023A CN 200510090722 CN200510090722 CN 200510090722 CN 200510090722 A CN200510090722 A CN 200510090722A CN 1730023 A CN1730023 A CN 1730023A
- Authority
- CN
- China
- Prior art keywords
- add
- preparation
- leaf
- recipe quantity
- total saponins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 28
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 241000700605 Viruses Species 0.000 title claims description 20
- 238000009472 formulation Methods 0.000 title claims description 12
- 238000000034 method Methods 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 106
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 100
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 100
- 235000008434 ginseng Nutrition 0.000 claims abstract description 100
- 229930182490 saponin Natural products 0.000 claims abstract description 99
- 150000007949 saponins Chemical class 0.000 claims abstract description 99
- 235000017709 saponins Nutrition 0.000 claims abstract description 99
- 239000002775 capsule Substances 0.000 claims abstract description 58
- 239000006187 pill Substances 0.000 claims abstract description 37
- 239000008187 granular material Substances 0.000 claims abstract description 36
- 239000007901 soft capsule Substances 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 28
- 239000006196 drop Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- 241000208340 Araliaceae Species 0.000 claims description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 70
- 239000003814 drug Substances 0.000 claims description 50
- 238000002156 mixing Methods 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000008030 elimination Effects 0.000 claims description 10
- 238000003379 elimination reaction Methods 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 abstract description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000012676 herbal extract Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010019799 Hepatitis viral Diseases 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 201000001862 viral hepatitis Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000272525 Anas platyrhynchos Species 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 4
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229930014456 matrine Natural products 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 241000272522 Anas Species 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 231100000012 chronic liver injury Toxicity 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- ZSBXGIUJOOQZMP-BHPKHCPMSA-N sophoridine Chemical compound C1CC[C@@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-BHPKHCPMSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000009243 biejia ruangan Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000008865 yin zhi huang Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 叶下珠以没食子酸(C7H6O5)计 | 人参茎叶总皂苷以人参皂苷Re(C48H82O18)计 |
本发明片剂mg/片 | 4.9 | 11.3 |
本发明胶囊剂mg/粒 | 5.3 | 10.9 |
本发明颗粒剂mg/片袋 | 5.2 | 11.0 |
本发明软胶囊剂mg/粒 | 4.8 | 11.0 |
本发明滴丸剂mg/10粒 | 5.0 | 11.2 |
本发明口服液 | 5.2 | 11.1 |
mg/瓶 | ||
本发明缓释片剂mg/片 | 5.3 | 11.2 |
本发明缓释胶囊剂mg/粒 | 5.1 | 11.0 |
组别 | 动物数只 | GPT(U-L-1) | GOT(U-L-1) | TP(g-L-1) | ALB(g-L-1)(g-L-1) |
对照组 | 10 | 19.56±2.00** | 330.95±4.53** | 7.92±0.44** | 4.73±0.28** |
模型组 | 10 | 125.6±19.80 | 182.32±57.77 | 5.81±0.70 | 3.29±0.37 |
联苯双酯组 | 10 | 41.6±7.74** | 60.04±7.26** | 7.73±1.19** | 4.29±0.55** |
本发明片剂 | 10 | 51.13±10.94** | 63.89±9.63** | 7.58±0.72** | 4.19±0.49** |
本发明胶囊剂 | 10 | 51.47±10.26** | 63.72±9.39** | 7.77±0.68** | 4.20±0.41** |
本发明颗粒剂 | 10 | 50.88±11.26** | 64.21±9.08** | 7.53±0.74** | 4.17±0.44** |
本发明软 | 10 | 51.59± | 63.9± | 7.62±0.75** | 4.15±0.50** |
胶囊剂 | 10.30** | 9.21** | |||
本发明滴丸剂 | 10 | 51.43±10.20** | 63.89±9.75** | 7.54±0.66** | 4.14±0.44** |
本发明口服液 | 10 | 51.27±10.18** | 64.04±9.52** | 7.85±0.59** | 4.19±0.47** |
本发明缓释片剂 | 10 | 51.13±10.94** | 64.11±9.88** | 7.74±0.85** | 4.12±0.49** |
本发明缓释胶囊剂 | 10 | 50.96±9.92** | 63.94±9.54** | 7.63±0.79** | 4.18±0.46** |
组别 | 动物数只 | DHBV-DNA水平T0 | DHBV-DNA水平T5 | DHBV-DNA水平T10 | DHBV-DNA水平P3 |
对照组 | 6 | 0.905±0.08 | 0.979±0.05 | 0.921±0.11 | 0.977±0.13 |
拉米夫定组 | 6 | 0.951±0.06 | 0.921±0.15 | 0.424±0.07** | 0.968±0.09 |
本发明片剂 | 6 | 0.931±0.13 | 0.776±0.09** | 0.699±0.11** | 0.597±0.11** |
本发明胶囊剂 | 6 | 0.927±0.11 | 0.774±0.08** | 0.680±0.10** | 0.595±0.10** |
本发明颗粒剂 | 6 | 0.930±0.12 | 0.777±0.08** | 0.689±0.14** | 0.588±0.14** |
本发明软胶囊剂 | 6 | 0.938±0.14 | 0.784±0.12** | 0.694±0.10** | 0.590±0.13** |
本发明滴丸剂 | 6 | 0.929±0.13 | 0.780±0.10** | 0.699±0.09** | 0.594±0.11** |
本发明口服液 | 6 | 0.931±0.12 | 0.779±0.08** | 0.692±0.13** | 0.597±0.09** |
本发明缓释片剂 | 6 | 0.930±0.17 | 0.781±0.11** | 0.688±0.10** | 0.587±0.12** |
本发明缓释胶囊剂 | 6 | 0.929±0.14 | 0.777±0.07** | 0.687±0.10** | 0.597±0.11** |
组别 | 动物数只 | GPT(U-L-1) | GOT(U-L-1) |
对照组 | 10 | 21.76±4.77** | 19.51±3.18** |
模型组 | 10 | 248.69±29.89 | 66.67±6.52 |
联苯双酯组 | 10 | 103.86±28.19* | 31.05±9.88** |
本发明片剂 | 10 | 139.47±37.68** | 35.92±10.24** |
本发明胶囊剂 | 10 | 138.52±35.42** | 34.17±10.33** |
本发明颗粒剂 | 10 | 137.89±37.62** | 35.02±10.58** |
本发明软胶囊剂 | 10 | 138.09±38.01** | 355.87±10.48** |
本发明滴丸剂 | 10 | 137.52±36.49** | 35.78±10.46** |
本发明口服液 | 10 | 138.26±35.47** | 34.89±10.39** |
本发明缓释片剂 | 10 | 135.44±39.28** | 35.92±10.27** |
本发明缓释胶囊剂 | 10 | 139.47±37.57** | 35.21±10.09** |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100907221A CN100388928C (zh) | 2005-08-15 | 2005-08-15 | 一种抗肝炎病毒的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100907221A CN100388928C (zh) | 2005-08-15 | 2005-08-15 | 一种抗肝炎病毒的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1730023A true CN1730023A (zh) | 2006-02-08 |
CN100388928C CN100388928C (zh) | 2008-05-21 |
Family
ID=35962469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100907221A Expired - Fee Related CN100388928C (zh) | 2005-08-15 | 2005-08-15 | 一种抗肝炎病毒的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100388928C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104770567A (zh) * | 2015-04-13 | 2015-07-15 | 广西南宁桂知科技有限公司 | 一种防治山瑞鳖肝炎病的饲料及其制备方法 |
CN104825531A (zh) * | 2015-05-29 | 2015-08-12 | 中国药科大学 | 一种具有抗肝损伤活性的药物组合物及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107412584A (zh) * | 2017-04-28 | 2017-12-01 | 防城港市中医医院 | 一种治疗肝炎的药物组合物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593472A (zh) * | 2003-09-10 | 2005-03-16 | 深圳市清华源兴生物医药科技有限公司 | 一类治疗肝脏疾病的药物组方及其应用 |
-
2005
- 2005-08-15 CN CNB2005100907221A patent/CN100388928C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104770567A (zh) * | 2015-04-13 | 2015-07-15 | 广西南宁桂知科技有限公司 | 一种防治山瑞鳖肝炎病的饲料及其制备方法 |
CN104825531A (zh) * | 2015-05-29 | 2015-08-12 | 中国药科大学 | 一种具有抗肝损伤活性的药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100388928C (zh) | 2008-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1526400A (zh) | 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 | |
CN1730023A (zh) | 一种抗肝炎病毒的中药制剂及其制备方法 | |
CN1293898C (zh) | 治疗病毒性肝炎的药物组合物的制备方法 | |
CN1895540A (zh) | 一种治疗心血管疾病的药物组合物及其制备方法和用途 | |
CN1682780A (zh) | 一种治疗尿毒症及肾阳虚、肾衰竭的药物及其制备方法 | |
CN1258372C (zh) | 治疗肠易激综合症的中药组合物及其制备方法 | |
CN101045077A (zh) | 一种胡芦巴口服固体制剂的制备方法及其应用 | |
CN1197641A (zh) | 含有鞣料云实素的药物 | |
CN1111412C (zh) | 三七总皂甙软胶囊及其制备工艺 | |
CN1336233A (zh) | 一种治疗乙肝的药物 | |
CN1220510C (zh) | 一种益气补血养心安神的中成药及其制备方法质量控制方法 | |
CN1814076A (zh) | 一种中药组合物的新用途 | |
CN101040934A (zh) | 一种由山楂叶与红景天制成的药物组合物 | |
CN1679693A (zh) | 一种治疗肝病的药物及其制备方法 | |
CN101062374A (zh) | 一种治疗癌症的中药组合物胶囊的制备方法及其产品 | |
CN1251745C (zh) | 一种治疗肝胆疾病的药物及其制备方法 | |
CN1042395C (zh) | 蚁王精口服液及其制备方法 | |
CN1742783A (zh) | 一种扶正益气天然药物制剂及其制备方法 | |
CN1839931A (zh) | 一种治疗心脑血管疾病的药物组合物及其制备方法 | |
CN1651002A (zh) | 一种中药药物组合物及制备方法和应用 | |
CN1442165A (zh) | 一种治疗慢性肾炎的中药及其制备方法 | |
CN1857404A (zh) | 一种可用于治疗病毒性肝炎的药物组合物及其制备方法 | |
CN1251712C (zh) | 一种治疗肝炎的中药组合物及其制备方法 | |
CN1650919A (zh) | 一种中药复方制剂的处方及其制剂制备方法和用途 | |
CN1562272A (zh) | 治疗继发性贫血、缺铁性贫血的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: 302 MILITARY HOSPITAL OF CHINA Free format text: FORMER OWNER: BAISHILIKANG MEDICINE SCIENCE AND TECHNOLOGY CO., LTD., BEIJING Effective date: 20100831 Owner name: BAISHILIKANG MEDICINE SCIENCE AND TECHNOLOGY CO., |
|
CB03 | Change of inventor or designer information |
Inventor after: Xiao Xiaohe Inventor after: Yi Xiaoping Inventor after: Wang Gabo Inventor after: Zhao Yanling Inventor after: Li Yonggang Inventor after: Luo Shengqiang Inventor after: Liu Shijing Inventor after: Yang Huiyin Inventor before: Yi Xiaoping |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YI XIAOPING TO: XIAO XIAOHE YI XIAOPING WANG JIABO ZHAO YANLING LI YONGGANG LUO SHENGQIANG LIU SHIJING YANG HUIYIN Free format text: CORRECT: ADDRESS; FROM: 102200 ROOM 307, NO.26, YONG'AN ROAD, CHANGPING SCIENCE AND TECHNOLOGY PARK, BEIJING TO: 100039 NO.100, W. 4TH RING MIDDLE ROAD, FENGTAI DISTRICT, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100831 Address after: 100039 No. 100 West Fourth Ring Road, Beijing, Fengtai Co-patentee after: Baishilikang Medicine Science and Technology Co., Ltd., Beijing Patentee after: 302 Military of China Address before: 102200, room 26, 307 Yongan Road, Changping science and Technology Park, Beijing Patentee before: Baishilikang Medicine Science and Technology Co., Ltd., Beijing |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080521 Termination date: 20180815 |
|
CF01 | Termination of patent right due to non-payment of annual fee |